SIBIA Inc., Bristol-Myers regulatory update

The companies will collaborate to discover and develop compounds to treat Alzheimer's disease. Bristol-Myers will provide research support and make milestone payments to SIBIA (San Diego) in return for exclusive commercial rights to products resulting from the effort. Bristol-Myers has paid an undisclosed licensing fee and purchased a minority equity interest in SIBIA. If all milestones are met, SIBIA could receive up to $50 million. SIBIA will receive royalties on product sales. ...